“We support (the administration’s) call for greater flexibility in benefit design to encourage better price negotiations…” PCMA said
See Infographic on prescription drug price increases in Medicare Part B
Sanofi and Regeneron have agreed to lower the price of their cholesterol medicine in exchange for easier access for patients covered by pharmacy benefit manager
“I think what happened is they looked at this policy very, very closely and found out it was a loser,” PCMA President Mark Merritt said.
Greater competition is the answer, Mr. Merritt said, and he praised recent efforts by the Food and Drug Administration
(Washington, D.C.) — As the Administration considers modifying price concessions for prescription drugs in Medicare and federal programs, the Pharmaceutical Care Management Association (PCMA) is releasing new data, “Reconsidering Drug Prices, Rebates, and PBMs,” showing drug manufacturers alone set prices –
Increasing list prices are not correlated with changes in prescription drug rebates.
“This extra year will help to reduce disruptions to Medicare beneficiaries by allowing Part D plans time to adjust their pay-for-performance pharmacy contracting,” PCMA said. “In addition, the delay appropriately prevents premiums from increasing in 2023 on top of rising inflation.”
“We are simply seeing more activity in the pharmacy space, which is leading to more business,” JC Scott, the head of the Pharmaceutical Care Management Association, the primary lobbying group for PBMs, told STAT. “There’s more demand for PBM services as a result of that.”
©2024 PCMA. All Rights Reserved.
